Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 4/20 | 0.55 |
| ▸ | CACNG8 | Q8WXS5 | 4/20 | 0.55 |
| ▸ | PGR | P06401 | 4/20 | 0.52 |
| ▸ | AHR | P35869 | 3/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18189657 | 0.96 | GRIA1 (0.53) | GRIA1CACNG8PGRAHRPDE3B | |
| SCHEMBL18189570 | 0.83 | GRIA1 (0.73) | GRIA1CACNG8PGRAHRPDE3B | |
| SCHEMBL18189429 | 0.81 | GRIA1 (0.60) | GRIA1CACNG8PGRAHRPDE3B | |
| SCHEMBL21533266 | 0.79 | AHR (0.41) | GRIA1CACNG8PGRAHRCMA1 | |
| SCHEMBL18189617 | 0.78 | GRIA1 (0.58) | GRIA1CACNG8PGRAHRPDE3B | |
| SCHEMBL18189567 | 0.77 | GRIA1 (0.55) | GRIA1CACNG8PGRAHRPDE3B | |
| SCHEMBL18189650 | 0.77 | GRIA1 (0.86) | GRIA1CACNG8PGRAHRPDE3B | |
| SCHEMBL18189548 | 0.77 | GRIA1 (0.67) | GRIA1CACNG8PGRAHRPDE3B | |
| SCHEMBL18189369 | 0.77 | GRIA1 (0.64) | GRIA1CACNG8PGRAHRPDE3B | |
| SCHEMBL18203050 | 0.77 | GRIA1 (0.63) | GRIA1CACNG8PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107750250-B | Indolone compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-09-07 | — | — | CN | claimed |
| EP-3288935-B1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-30 | — | — | EP | claimed |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | claimed |
| EP-3288935-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | claimed |
| WO-2016176463-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | claimed |
| CN-107750250-B | Indolone compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-31 | — | — | US | disclosed |
| EP-3288935-B1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| EP-3288935-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016176463-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016176463-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | GRIN3A, GRIN1, GRIN2B | GRIA1 23/4885CACNG8 317/4885PGR 587/4885 |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN1, GRIN2B | GRIA1 23/4885CACNG8 317/4885PGR 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.